References
- Godman B, Novakovic T, Tesic D, et al. Addressing challenges for sustainable healthcare in Central and Eastern Europe. Expert Rev Pharmacoecon Outcomes Res. 2016;16(6):685–687.
- Putrik P, Ramiro S, Kvien TK, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73(1):198–206.
- Kostic M, Djakovic L, Sujic R, et al. Inflammatory bowel diseases (Crohn’s disease and ulcerative colitis): cost of treatment in Serbia and the implications. Appl Health Econ Health Policy. 2017;15(1):85–93.
- Bochenek T, Kocot E, Rodzinka M, et al. The transparency of published health technology assessment-based recommendations on pharmaceutical reimbursement in Poland. Expert Rev Pharmacoecon Outcomes Res. 2017 Aug;17(4):385–340.
- Kennedy I. Appraising the value of innovation and other benefits. A short study for nice. 2009. [cited 2017 Jun 14]. Available from: https://www.nice.org.uk/Media/Default/About/what-we-do/Research-and-development/Kennedy-study-final-report.pdf.
- Prata WM, Silvestre RG, Godman B, et al. A critical look at innovation profile and its relationship with pharmaceutical industry. Int J Scientific Res Manag (IJSRM). 2017;5(7):934–5948.
- RFZO. Health insurance documentation. [cited 2017 Jun 12]. Available from: http://www.rfzo.rs/index.php/dokumenta.
- Ferrario A, Kanavos P. Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden. Soc Sci Med. 2015;124:39–47.
- Ferrario A, Kanavos P Managed entry agreements for pharmaceuticals: the European experience. EMiNet, Brussels, Belgium. [cited 2017 Jun 12]. Available from: http://eprints.lse.ac.uk/50513/2013
- Ferrario A, Arāja D, Bochenek T, et al. The implementation of managed entry agreements in Central and Eastern Europe: findings and implications. Pharmacoeconomics. 2017 Aug 23. DOI:10.1007/s40273-017-0559-4
- Grimm S, Strong M, Brennan A, et al. Framework for analysing risk in health technology assessments and its application to managed entry agreements. Report by the decision support unit. [cited 2017 Jun 14]. Available from: http://scharr.dept.shef.ac.uk/nicedsu/wp-content/uploads/sites/7/2016/03/DSU-Managed-Access-report-FINAL.pdf
- Grimm SE, Strong M, Brennan A, et al. The HTA risk analysis chart: visualising the need for and potential value of managed entry agreements in health technology assessment. PharmacoEconomics. 2017.
- Klimeš JFL, Vocelka M. Access to innovative medicines in the Czech Republic: length of price and reimbursement (P&R) procedures. Value Health. 2016;19(7):A448.
- Hosseinpoor AR, Bergen N, Koller T, et al. Equity-oriented monitoring in the context of universal health coverage. PLoS Med. 2014;11(9):e1001727.
- Malmstrom RE, Godman BB, Diogene E, et al. Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol. 2013;4:39.
- Godman B, Finlayson AE, Cheema PK, et al. Personalizing health care: feasibility and future implications. BMC Med. 2013;11:179.
- NHS. NHS RightCare. [cited 2017 Jun 10]. Available from: https://www.england.nhs.uk/rightcare/what-is-nhs-rightcare/
- Kotsopoulos N, Connolly MP, Postma MJ, et al. Fiscal consequences of changes in morbidity and mortality attributed to rotavirus immunisation. Vaccine. 2013;31(46):5430–5434.
- Kotsopoulos N, Connolly MP, Remy V. Quantifying the broader economic consequences of quadrivalent human papillomavirus (HPV) vaccination in Germany applying a government perspective framework. Health Econ Rev. 2015;5(1):54.
- Connolly MP, Kotsopoulos N, Postma MJ, et al. The fiscal consequences attributed to changes in morbidity and mortality linked to investments in health care: a government perspective analytic framework. Value Health. 2017;20(2):273–277.